A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Condition(s):Stage II-IIIB Non-small Cell Lung CarcinomaLast Updated:March 12, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Stage II-IIIB Non-small Cell Lung CarcinomaLast Updated:March 12, 2024Recruiting
Condition(s):Non-squamous NSCLCLast Updated:January 23, 2024Not yet recruiting
Condition(s):NSCLC; EGFR Positive Non-small Cell Lung Cancer; OligoprogressionLast Updated:December 26, 2023Recruiting
Condition(s):NSCLC, Stage ILast Updated:January 17, 2023Recruiting
Condition(s):CancerLast Updated:March 5, 2024Recruiting
Condition(s):Lung AdenocarcinomaLast Updated:May 15, 2023Recruiting
Condition(s):Carcinoma, Non-Small-Cell LungLast Updated:October 31, 2023Recruiting
Condition(s):Non-squamous NSCLCLast Updated:June 2, 2023Active, not recruiting
Condition(s):NSCLC Stage IV; EGFR Gene MutationLast Updated:November 2, 2023Active, not recruiting
Condition(s):NSCLCLast Updated:May 3, 2021Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.